Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm provides MPS Clinical Program update
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Quarterly Update and Appendix 4C - quarterly
- Paradigm Partners with NFL Alumni Health for OA Program
- Paradigm reports global progress in phase 3 study
- 100% Recruitment in Synovial Fluid Biomarker Trial
- Paradigm Reports Australian Patent Acceptance
Later from Paradigm Biopharmaceuticals
- Paradigm Launches $66M Capital Raising
- Investor Presentation - $66m Capital Raise
- PAR Non-Renounceable Rights Issue Offer Booklet
- 2022 Annual Report and Appendix 4E
- Successful Completion of Entitlement Offer
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals